The Clinical Trial of Low Dose Irradiation for Alzheimer's Disease

Inclusion Criteria:

All of the following criteria are satisfied for the subjects to be included in the study:

1. Aged between 60 and 85 years.

2. Diagnosed with probable Alzheimer's disease (AD) dementia based on the newdiagnostic criteria for Alzheimer's disease outlined by the National Institute onAging and Alzheimer's Association (NIA-AA).

3. Stably maintaining the general AD drug treatment (donepezil, galantamine,rivastigmine, or memantine) for more than 3 months.

4. Amyloid accumulation in brain confirmed by Amyloid PET.

5. Mild AD (score range of 13 to 24 on the Korean Mini-Mental State Examination (K-MMSE) or 0.5 or 1 on the Clinical Dementia Rating scale (CDR)).

6. Able to perform cognitive function tests and imaging tests.

7. Accompanied by a guardian who provides information on the subject's overall status,cognitive function, and functional changes.

8. Written informed consent was provided by the subject or the guardian to participatein this trial.

Exclusion Criteria:

Subjects who fall under any of the following criteria are excluded from the study:

1. Previous history of radiation to the brain.

2. History of seizure within the previous 10 years of the screening time.

3. Skin disease on the scalp.

4. Previous history of malignancy.

5. Pregnancy or breastfeeding.

6. Subjects with cognitive decline associated with drugs or neurological /neurodegenerative conditions, not AD (i.e., drug abuse, vitamin B12 deficiency,thyroid dysfunction, stroke or other cerebrovascular conditions, Lewy body dementia,frontotemporal dementia, and head trauma).

7. Clinically significant, unstable mental illness (i.e., uncontrolled depression,schizophrenia, and bipolar disorder) within the last 6 months.

8. Subjects whose brain MRI confirms evidence of: acute or subacute hemorrhage, priormacro hemorrhage (defined as >1 cm in diameter, T2 sequence) or prior subarachnoidhemorrhage unless it can be documented that the finding is not due to an underlyingstructural or vascular abnormality, more than 4 microhemorrhages, cortical infarct (defined as >1.5 cm in diameter, irrespective of anatomic location), >1 lacunarinfarct (defined as >1.5 cm in diameter), superficial siderosis, and history ofdiffuse white matter disease as defined by a score of 3 on the age-related whitematter changes scale. Any finding that, in the opinion of the investigator, might bea contributing cause of the subject's dementia, or pose a risk to the subject, ormight prevent a satisfactory MRI assessment for safety monitoring are also includedin the exclusion criteria.

9. Those who have other findings that are considered clinically important, and thosewho are judged by the researcher to be inappropriate for participation in thisstudy.